Among the late-stage clinical trials are the phase III TROPION-Lung01 trial, which showed a 65% ORR in EGFR-mut NSCLC (NCT05215340), and the LOXO-783 (PI3Kα H1047R) phase II trial, with a 38% ORR in PIK3CA-mutant breast cancer (NCT05307705), as well as the KN-4802 (dual EGFR/MET) phase II trial, which showed that the drug overcomes osimertinib resistance via MET amplification (56% ORR; NCT05526736). Here, EGFR is linked to breast carcinoma.